VelosBio Inc. clinical trials
Acquired by Merck & Co., Inc, Dec 2020 · source ↗
The registry lists 2 studies whose lead sponsor is VelosBio Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2025.
- 2studies on the registry
- 0open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before VelosBio Inc. became part of Merck & Co., Inc
- 2
- First submitted after VelosBio Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs VelosBio Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 2
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 119
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Merck & Co., Inc studies →
- A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)TerminatedNCT04504916Phase 2
Sponsor listed in the registry: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before VelosBio Inc. became part of Merck & Co., Inc
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
Sponsor listed in the registry: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before VelosBio Inc. became part of Merck & Co., Inc